Upstream Bio (UPB) Interest Coverage Ratio (2023 - 2026)
Upstream Bio's (UPB) quarterly Interest Coverage Ratio came in at 2.05 in Q1 2026, up 51.26% year-on-year from 1.36 in Q1 2025, and down 622.29% quarter-over-quarter from 0.28 in Q4 2025.
Upstream Bio (UPB) Interest Coverage Ratio (2023 - 2026) Analysis & Trends
Upstream Bio's Interest Coverage Ratio history runs 4 years deep, the most recent figure standing at 2.05 for Q1 2026.
- On a quarterly basis, Interest Coverage Ratio rose 51.26% year-over-year to 2.05 in Q1 2026; TTM through Mar 2026 was 8.1, a 35.08% increase from a year earlier, with the FY2025 full-year figure at 0.99, up 9.44% from the prior year.
- Interest Coverage Ratio retreated to 2.05 in Q1 2026 per UPB's latest filing, from 0.28 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 0.28 in Q4 2025 and bottomed at 4.22 in Q1 2025.
- The 4-year median for Interest Coverage Ratio is 0.46 (2024), against an average of 1.17.
- Across the five-year window, Interest Coverage Ratio declined 2.3% in 2024 and jumped 51.26% in 2026, its largest moves.
- Year by year, Interest Coverage Ratio stood at 0.36 in 2023, then decreased by 2.3% to 0.37 in 2024, then grew by 22.96% to 0.28 in 2025, then tumbled by 622.29% to 2.05 in 2026.
- Per Business Quant, the three latest UPB Interest Coverage Ratio figures stand at 2.05 (Q1 2026), 0.28 (Q4 2025), and 0.38 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - | - |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - | -157.58 |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn | 7.60 |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn | 3.88 |
| 10 | Upstream Bio | 347.18 Mn | 347.18 Mn | -3.94 Mn | -2.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.05 |
| Dec 31, 2025 | -0.28 |
| Sep 30, 2025 | -0.38 |
| Jun 30, 2025 | -1.12 |
| Mar 31, 2025 | -4.22 |
| Dec 31, 2024 | -0.37 |
| Sep 30, 2024 | -0.54 |
| Dec 31, 2023 | -0.36 |